Nanomedicine in organ transplantation and regenerative surgery – advances, applications and future directions – an interview

Commissioning Editor Lucy Chard speaks with Guest Editors Jelena Janjic (Duquesne University School of Pharmacy; PA, USA) and Vijay Gorantla (Wake Forest Institute for Regenerative Medicine; NC, USA).

Go to the profile of Nanomedicine
Nov 20, 2019
0
0

In this interview, Commissioning Editor Lucy Chard discusses the recently published Special Focus Issue (SFI) of the journal Nanomedicine with Guest Editors Jelena Janjic (Duquesne University School of Pharmacy; PA, USA) and Vijay Gorantla (Wake Forest Institute for Regenerative Medicine; NC, USA).

The SFI, entitled ‘Nanomedicine in Organ Transplantation and Regenerative Surgery – Advances, Applications and Future Directions’, highlights the applications of nanomedicine for therapeutic, diagnostic and monitoring strategies in solid organ transplantation. Check out the SFI now>>


How did you become involved in researching nanomedicine in organ transplantation and regenerative surgery? 

Jelena Janjic (JJ): I started my career in nanotechnology and nanomedicine in 2006 at Carnegie Mellon University in Pittsburgh (PA, USA). For more than a decade, my lab at Duquesne University (PA, USA) has focused on theranostic technologies, specifically related to pain nanomedicine. 

Vijay Gorantla (VG): I have been involved in clinical and experimental vascularized composite allotransplantation (VCA) since 1999. I was part of the team that performed the first hand transplant in the United States. Over the past two decades I have had exposure to both medical and research aspects of this field and the opportunity to direct the care of several hand transplant recipients.  The overarching challenge in VCA is the burden of transplant immunosuppression. We need to rethink and recast transplant medicine in the context of cancer nanomedicine where advancements have focused on reducing complications and improving outcomes. Novel procedures such as VCA stand to change the lives of millions of people, especially those who are disabled or living with devastating injuries which lack any other standard options.


How did you first begin working together on this topic?

JJ: Dr. Gorantla and I began exploring collaborations in applications for nanomedicine in transplantation and regenerative medicine about three years ago. Work across our labs spans several areas of nanomedicine. Some joint funded projects address nanomedicine applications such as nanoimaging or theranostics in areas such as peripheral nerve injury, nerve regeneration, immune rejection and tissue preservation. 


Why is this research an area of unmet need and what challenges are faced in the field?

JJ: We both share similar views on the unmet need, coming from very different perspectives. As a pharmacist and medicinal chemist, nanomedicine offers the unique potential for multifunctionality. For example, we could develop a formulation that can carry single or multiple drugs or agents with different mechanisms of action, which can be precisely delivered to specific cells or tissues of interest, and then monitored for activity, treatment response and toxicity. Such theranostic nanomedicine has begun to revolutionize cancer treatment and holds tremendous potential in regenerative medicine or transplantation. Despite such capabilities, nanosystems must be designed with cost and scalability in mind, without which clinical feasibility would be a challenge. 

VG: If you look at the advancements and developments in transplantation medicine over the past forty years, only five drugs have been FDA approved for management of organ transplant rejection. These include cyclosporine (FDA approved in 1983), tacrolimus (FDA approved in 1994), mycophenolate mofetil (FDA approved in 1995), rapamycin (FDA approved in 1999) and most recently belatacept (FDA approved in 2011).  Tacrolimus continues to be the major drug in standard organ transplants as well as VCA despite its wide-ranging side effects.  In comparison, over the same period, around 200 drugs have been FDA approved for cancer applications versus five drugs in transplantation. Innovation and investment in transplantation medicine has starkly lagged behind oncology. The comparison with oncology is important because it has heavily been in the focus for nanomedicine. 

For over 50 years, the overwhelming focus of transplant medicine has been to treat the recipient to prevent rejection in the graft. The question becomes, why don’t we use the same approaches in transplantation as in cancer where treatment is targeted to the cancerous cells or tissues? If we can deliver the anti-rejection drugs predominantly or solely to the graft tissues, we can spare the recipient from the toxicity of the immunosuppression.  In essence, we need a paradigm shift in our approach to transplant rejection. 

Nanomedicine can deliver ultra-low dose medication to the donor cells or graft tissues, and nano-imaging can enable graft surveillance through non-invasive immunomonitoring of donor and recipient cells. Together, we can precisely tune and personalize therapies while minimizing adverse effects as seen with systemic treatments. Beyond improvement in outcomes, the economic justification and savings in healthcare dollars through nanomedicine strategies could be significant.


Do you think the SFI will have a big impact on the field?

JJ: Well, the answer is: definitely. The SFI offers an integrated multidisciplinary view of the unmet needs and technological advancements in nanomedicine with the specific goal of raising awareness among transplant and regenerative medicine specialists for such technologies. 

VG: Jelena and I had a vision to bring an issue to the readers that is totally contemporary in terms of topics reviewing therapeutic, diagnostic or monitoring approaches in transplantation or regenerative surgery based on nanomedicine technologies. In addition to promoting peer awareness, the impact we aim for is greater adoption and incorporation of nanomedicine approaches into transplant medicine. 


You were both the authors on the review article “Pharmaceutical Design and Development of Perfluorocarbon Nanocolloids for Oxygen Delivery in Regenerative Medicine” which features in the SFI. Could you give a very brief introduction of this paper and your rationale for investigating this area?

VG: Tissue preservation is a critical goal in organ transplantation. Despite significant research, funding and investments into hemoglobin substitutes and other artificial oxygen carriers, reliable oxygenation and preservation of tissues remains a challenge. In contrast to current oxygenated perfusates, nanocarriers that deliver oxygen into cells can help better optimize oxygenation, facilitating cell metabolism and survival in regeneration or transplantation indications.

JJ: A key focus of this article is quality design and manufacturing on scale of oxygen carrying nanocolloids that are perfectly optimized for cell or tissue oxygenation without the residual toxic side effects of free radicals. These nanocolloids can be loaded with imaging agents to enable non-invasive imaging to monitor ischemia or reperfusion injury events. 


Where do you see the field progressing in the next five to 10 years? 

VG: We are currently in a moment in transplantation where there is a lot of opportunity and unmet need for technologies or therapies that eliminate the side effects and long-term toxicity of immunosuppressant drugs. Advancements in nanomedicine, could help not only better diagnose rejection, but also monitor its response to treatment or relapse or resistance to intervention.  That is where I think we will see a lot of advancements in the next five to 10 years.

Beyond transplantation, we will also see a lot of advancements in regenerative medicine, especially in the area of bioengineering and tissue engineering. Nanomedicine can be used to generate novel tissues or tissue interfaces, as well as bioartificial constructs or 3D tissue constructs and integrating those constructs without the risk of fibrosis, functional compromise or rejection. 

JJ: With advancements in pharmaceutical development and quality by design strategies, I am hopeful that nanomedicine will become mainstream and accessible to patients worldwide, especially in areas of regenerative medicine or transplantation where you need long-term treatment with personalization. 


For this issue you have worked with experts from all over the world. Is this global level of collaboration something that you had in mind when you started the issue?

JJ: Innovation in nanomedicine requires multi-disciplinary collaboration across disparate and wide-ranging specialties. This is why we engaged subject matter experts from diverse backgrounds to contribute and highlight the latest advancements in nanomedicine and potential applications in transplant or regenerative medicine. 

VG: Nanomedicine applications in regenerative medicine or transplantation require convergent knowledge.  Multiple specialties must come together to create the tools, technologies or therapies that are the most optimal, most safe and most efficacious. 


Then to sum up, if you have any final comments that you would like mentioned?

JJ: We sincerely hope the special topics address the opportunities and challenges but also highlight the unmet need and the state-of-the-art applications of nanomedicine in transplantation.

VG: This first special issue is somewhat limited in its focus to organ transplants, reconstructive surgery and tissue engineering, and regenerative medicine applications of nanomedicine. We expect to work on future issues to highlight groundbreaking advances in these areas. 


Disclaimer:
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.

Financial & competing interests disclosure:
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.


Go to the profile of Nanomedicine

Nanomedicine

Journal, Future Science Group

Nanomedicine (Impact Factor: 4.717 [2018), is an award-winning peer-reviewed journal from Future Science Group, available in both print and online formats. Published 24 times per year, Nanomedicine is a uniquely medicine-focused journal, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats. Nanomedicine is listed by Medline/PubMed, Science Citation Index Expanded, Journal Citation Reports/Science Edition, Current Contents/Life Sciences and the Biotechnology Citation Index. Professor Kostas Kostarelos (Nanomedicine Lab, University of Manchester, UK) is the journal’s Senior Editor. You can find out more about Nanomedicine on our website (http://www.futuremedicine.com/loi/nnm), including the journal’s aims and scope and details of our international editorial board.

No comments yet.